Commercial Drugmakers battle for slice of Humira's billions

Drugmakers battle for slice of Humira's billions

Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.

Pipeline MedImmune goes after challenging lupus market

MedImmune goes after challenging lupus market

While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.

Commercial Top 25 autoimmune brands in 2016, based on U.S. sales

Top 25 autoimmune brands in 2016, based on U.S. sales

AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.

Features Read the complete April 2017 digital edition

Read the complete April 2017 digital edition

Here you'll find everything you need to know from MM&M's April 2017 issue, including our DTC report, our deep dive into respiratory drugs, and more.

Commercial 5 of healthcare's hardest nuts to crack

5 of healthcare's hardest nuts to crack

How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?

MMM Hall of Femme Hall of Femme of 2017

Hall of Femme of 2017

For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.

Commercial How pharma marketers are using behavioral science

How pharma marketers are using behavioral science

A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.

Top 40 Transformers Top 40 Healthcare Transformers of 2017

Top 40 Healthcare Transformers of 2017

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts Top 10 Innovation Catalysts of 2017

Top 10 Innovation Catalysts of 2017

For the first time MM&M honors a group of 10 agency execs.

Data/Analytics Infographic: The physician view on patient data

Infographic: The physician view on patient data

A WebMD survey finds that patients are more engaged when they share their own health with their doctors.

Campaigns What doctors have to say about those DTC ads

What doctors have to say about those DTC ads

We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.

Campaigns The 2017 DTC Report: All the data in one place

The 2017 DTC Report: All the data in one place

Drugmakers again spent more on DTC advertising in 2016 than the year before.

Campaigns Patients are taking on DTC ads. How will drugmakers respond?

Patients are taking on DTC ads. How will drugmakers respond?

Pharma spent more than $4 billion on TV ads last year. Empowered patient communities weren't impressed. Has DTC on TV reached its moment of reckoning?

Commercial Pro Ad Report: All the data on medical journal spending in 2016

Pro Ad Report: All the data on medical journal spending in 2016

The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.

Careers What five different pharma marketing careers look like

What five different pharma marketing careers look like

Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.

Features Read the complete March 2017 digital edition

Read the complete March 2017 digital edition

Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, and more.

Careers Roundtable: How healthcare agencies can retain and attract A-list talent

Roundtable: How healthcare agencies can retain and attract A-list talent

Seven execs from A-list agencies weigh in on talent acquisition and retention.

Commercial Top 25 respiratory brands, by sales

Top 25 respiratory brands, by sales

While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.

Pipeline Novartis aims to bring first oral asthma drug to market in two decades

Novartis aims to bring first oral asthma drug to market in two decades

An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.

Commercial Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Features Read the complete February 2017 digital edition

Read the complete February 2017 digital edition

Here you'll find everything you need to know from MM&M's February 2017 issue, including our payer state of the union, social media spotlight, and more.

Commercial Some CME experts remain skeptical when it comes to social media

Some CME experts remain skeptical when it comes to social media

There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.

Data/Analytics Infographic: What's next for the point of care market

Infographic: What's next for the point of care market

About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.

Commercial Why Philips' Erik Hollander turned to reinvention

Why Philips' Erik Hollander turned to reinvention

He describes his current charge as "transforming a more creative occupation into a science."

Sponsored Guidemark Health's Sophy Regelous on why small budgets are increasing

Guidemark Health's Sophy Regelous on why small budgets are increasing

Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.

Campaigns What uncertainty? 72% of health marketers say 2017 budgets are up

What uncertainty? 72% of health marketers say 2017 budgets are up

This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.

Features Read the complete January 2017 digital edition

Read the complete January 2017 digital edition

Here you'll find everything you need to know from MM&M's January 2017 issue, including our health-tech preview, a deep dive into data science, and report on digital innovation from Japanese drugmakers.

Pipeline Roche gears up to enter loaded hemophilia A drug market

Roche gears up to enter loaded hemophilia A drug market

A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.

Commercial Top 25 rare disease brands, by sales

Top 25 rare disease brands, by sales

Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.

Commercial Orphan drugs face criticism on prices — and from patients

Orphan drugs face criticism on prices — and from patients

When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."

Campaigns Marketers take a new approach to lung-cancer campaigns, and why that matters

Marketers take a new approach to lung-cancer campaigns, and why that matters

Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.

Campaigns How can drugmakers tell better stories? Try Instagram

How can drugmakers tell better stories? Try Instagram

The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.

Payers/Managed Markets Infographic: What payers want from pharma

Infographic: What payers want from pharma

One pharmacy director would like to see a lot more comparative data about new therapies.

Commercial Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Agencies Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.

Agencies Ryan Abbate, 2017 MAHF inductee, sets the record straight

Ryan Abbate, 2017 MAHF inductee, sets the record straight

The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.

Pipeline Lexicon developing type 1 diabetes treatment with Sanofi

Lexicon developing type 1 diabetes treatment with Sanofi

Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.

Commercial Top 25 metabolic brands, by sales, 2015-2016

Top 25 metabolic brands, by sales, 2015-2016

Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.

Commercial When it comes to diabetes, will marketers break with tradition?

When it comes to diabetes, will marketers break with tradition?

That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"

Legal/Regulatory Trump administration raises questions for rare-disease drugmakers

Trump administration raises questions for rare-disease drugmakers

Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.

Commercial If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

"In Australia, we are the healthcare industry," he says.

Data/Analytics Infographic: Can pharma give doctors what they want?

Infographic: Can pharma give doctors what they want?

Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?

Commercial Top 25 cardiovascular brands, 2015-2016

Top 25 cardiovascular brands, 2015-2016

The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.

Therapeutic Focus For statin-intolerant patients, what's next?

For statin-intolerant patients, what's next?

Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.

Commercial When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

Technology Japanese drugmakers lead the way in digital innovation

Japanese drugmakers lead the way in digital innovation

Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.

Features Shark Tank's Herjavec shares his tips for innovation competitions

Shark Tank's Herjavec shares his tips for innovation competitions

When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.

Data/Analytics Big data expert Hilary Mason on 3 ways to create a data-driven culture

Big data expert Hilary Mason on 3 ways to create a data-driven culture

The first step is to seek leadership support, she says.

Data/Analytics Why healthbots may eat search ads and mobile apps

Why healthbots may eat search ads and mobile apps

The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.

Data/Analytics Pharma adopts data-science culture in move toward AI

Pharma adopts data-science culture in move toward AI

Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.

Features Read the complete December 2016 digital edition

Read the complete December 2016 digital edition

Here you'll find everything you need to know from MM&M's December 2016 issue, including our policy outlook for pharma in a Republican-led White House and Congress and the exclusive pipeline report.

Pipeline The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

Here's a look at 100 experimental therapies in late-stage clinical trials.

Commercial The doctor-patient dialogue: As productive as it's ever been or broken?

The doctor-patient dialogue: As productive as it's ever been or broken?

More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.

Commercial Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.

Legal/Regulatory Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Commercial Infographic: what information doctors need from pharma

Infographic: what information doctors need from pharma

How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information

Campaigns Drugmakers, facing pricing criticism, sell cures in new ads

Drugmakers, facing pricing criticism, sell cures in new ads

With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?

Technology 3 health tech innovations experts say will revolutionalize healthcare

3 health tech innovations experts say will revolutionalize healthcare

As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare.

Commercial Insurers seek to challenge millennial 'invincibility'

Insurers seek to challenge millennial 'invincibility'

Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.

Features

Health Influencer 50: No. 1

Features

Health Influencer 50: No. 2

Features

Health Influencer 50: No. 3

Features

Health Influencer 50: No. 4

Features

Health Influencer 50: No. 5

Features

Health Influencer 50: No. 6

Features

Health Influencer 50: No. 7

Features

Health Influencer 50: No. 8

Features

Health Influencer 50: No. 9

Features

Health Influencer 50: No. 10

Features Health Influencer 50: 20-11

Health Influencer 50: 20-11

Features Health Influencer 50: 30-21

Health Influencer 50: 30-21

Features Health Influencer 50: 40-31

Health Influencer 50: 40-31

Features Health Influencer 50: 50-41

Health Influencer 50: 50-41

Features Health Influencer 50

Health Influencer 50

MM&M and PRWeek editors convened to select 50 battle-tested pros who are changing the healthcare game. Find out if you made the list.

Features Read the complete October 2016 digital edition

Read the complete October 2016 digital edition

Here you'll find everything you need to know from MM&M's 50th anniversary issue, including the story behind Viagra, the death of tchotchkes, and much more.

Pipeline If Roche's Ocrevus is approved, the already competitive MS market will gain another player

If Roche's Ocrevus is approved, the already competitive MS market will gain another player

The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.

Commercial Top 25 neurology products, based on 2016 sales forecasts

Top 25 neurology products, based on 2016 sales forecasts

MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.

Pipeline New science drives biopharma interest in neurological conditions

New science drives biopharma interest in neurological conditions

The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.

People Moves EMD Serono promotes Craig Millian to SVP of neurology and immunology

EMD Serono promotes Craig Millian to SVP of neurology and immunology

Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.

Careers Carling's Sherri Wilkins on her first creative break

Carling's Sherri Wilkins on her first creative break

The chief creative officer at Carling Communications talks about how she learned that the best leaders are only as good as the performance of their team.

Commercial Pro ad report: All the data on journal spending in 1H 2016

Pro ad report: All the data on journal spending in 1H 2016

Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.

Features Read the complete September 2016 digital edition

Read the complete September 2016 digital edition

Here, you'll find everything you need to know about MM&M's 2016 Career and Salary Survey, including data on salaries and agency employment trends.

Legal/Regulatory Why the FDA's view of patient communication evolved over time

Why the FDA's view of patient communication evolved over time

The agency's ambitions were fueled in part by external criticism. The barbs that stung most sharply were ones suggesting a certain indifference on the FDA's part.

Payers/Managed Markets Power to the payers: PBMs leave behind a trail of tiers

Power to the payers: PBMs leave behind a trail of tiers

When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.

Campaigns 30 years later, DTC's complicated past still hasn't deterred marketers

30 years later, DTC's complicated past still hasn't deterred marketers

Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.

Commercial 7 ways Viagra changed how drugs are marketed

7 ways Viagra changed how drugs are marketed

The inside story on a campaign for the ages, as told by the individuals who worked on it.

Campaigns Merck's creative archive tells an industry story

Merck's creative archive tells an industry story

Did you know that Norman Rockwell was a medical illustrator for Merck?

Commercial The provider gift ban: The day the tchotchkes died

The provider gift ban: The day the tchotchkes died

For some people in the industry ecosystem, the appeal of promo knickknacks endures.

Commercial How five therapies changed the course of pharma history

How five therapies changed the course of pharma history

And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.

At Work With WebMD's Leming on audience development and lessons from CNN.com

WebMD's Leming on audience development and lessons from CNN.com

The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.

Careers What do employers want? We ask three execs for their secrets and their insights

What do employers want? We ask three execs for their secrets and their insights

They share their insights, secrets, worries, and everything else in between.

Careers The industry's winning — and losing — job titles, based on salary

The industry's winning — and losing — job titles, based on salary

Hint: it pays to be an EVP.

Sponsored Sudler New York's John Marchese on the New Talent Pool

Sudler New York's John Marchese on the New Talent Pool

"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."

Careers Pharma marketing salaries veer off track, dropping 2.6% in 2016

Pharma marketing salaries veer off track, dropping 2.6% in 2016

Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.

Sponsored Data, Technology, and Medicine: How They Intersect

Data, Technology, and Medicine: How They Intersect

The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.

Commercial Infographic: How physicians share online info with patients and other docs

Infographic: How physicians share online info with patients and other docs

The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.

Commercial Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

Commercial The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

Commercial Drugmakers revive R&D focus on long stagnant women's health market

Drugmakers revive R&D focus on long stagnant women's health market

Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?

Commercial Top 25 women's health products, ranked by 2016 forecasts

Top 25 women's health products, ranked by 2016 forecasts

Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.